Replimune Group, Inc. (REPL) has been one of the more dramatic biotechnology stories of the year, rebounding from a 52-week low near $1.50 to roughly $19.50 after winning a landmark U.S. Food and Drug Administration (FDA) approval and beginning the commercial launch of its first product. The question now facing investors is whether the rally has further to run, and specifically whether the shares can reach the $22 level implied by current sell-side targets.
The $22 central target reflects seven individual targets attributable to named firms. The most recent revisions came after the company's fiscal second-quarter 2027 update, when Jefferies analyst Roger Song raised his target to $29 from $24 (Buy), and Leerink Partners lifted its target to $31 from $19 (Outperform). Elsewhere, J.P. Morgan stands at $21, BMO Capital and Wedbush at $19, Kempen & Co at $19, and Piper Sandler at $14. The simple average of these seven figures is about $21.86, which rounds to $22.
Notably, that mean is not a formal published consensus, and the dispersion is wide. Bullish firms argue the melanoma franchise can scale quickly and justify a premium valuation; more cautious analysts point to a clinical-stage balance sheet and a launch that has yet to generate meaningful revenue. The $14-to-$31 spread underscores how much of the target debate hinges on unproven sales, not on near-term financials.
Replimune closed near $19.49 on November 2, 2026, within a whisker of its 52-week high. Reaching $22 would require roughly a 12.9% gain — modest relative to the stock's recent volatility, but not automatic. The company remains unprofitable, with no trailing revenue and a net loss of roughly $57.1 million in its latest quarter.
The path to $22 therefore runs through commercial execution. Replimune's first product, TUDRIQEV (vusolimogene oderparepvec, or RP1), received FDA accelerated approval for adults with advanced melanoma who have progressed on a PD-1-based regimen, and is administered in combination with nivolumab. The company reported that more than 15 institutions had begun prescribing the drug, that it had contacted over 70% of its first 200 target accounts, and that cash of about $307.8 million provides a runway of more than 12 months.
Several factors could underpin further upside. The FDA approval transformed Replimune from a binary clinical-stage story into a company with an actual marketed therapy, and early signs of formulary access and prescribing activity suggest demand is materializing. A narrower-than-expected quarterly loss also signals improving expense discipline. Bullish analysts see a sizable market opportunity in advanced melanoma and a pipeline (RP2, RP3) that could broaden the platform. Positive analyst revisions, with multiple firms raising targets in recent weeks, have reinforced upward momentum.
The principal obstacle is that the commercial launch is still unproven. Revenues have yet to materialize, and Replimune competes against established melanoma treatments. The company is loss-making and has relied on equity financing, including a roughly $150 million offering in August 2026, which can dilute existing shareholders. Elevated short interest of roughly 24% of the float suggests meaningful skepticism, and several securities class action lawsuits were filed following the stock's earlier collapse. A slower-than-expected launch, disappointing pricing, or a regulatory setback could pressure the valuation.
The stock trades far above its 50-day moving average near $13.60 and its 200-day moving average near $9.35, and its RSI (relative strength index, a momentum gauge) sits above 70, a zone often associated with overbought conditions. The shares recently broke decisively above the $16-to-$18 range to make new 52-week highs, leaving the $17-to-$18 area as a potential support zone on any pullback, while the round $20 level and the prior high near $19.68 represent near-term resistance between the current price and $22.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms differ, and the wide $14-to-$31 range means the appropriate time frame is uncertain. Investors should watch quarterly revenue disclosures for the first hard evidence of TUDRIQEV sales, prescribing and formulary metrics, cash-burn trends, any additional financing, and further analyst revisions. Regulatory updates on the confirmatory trials and pipeline readouts will also matter for the long-term valuation.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Replimune, such signals can help traders spot shifting momentum and manage positions more systematically. Traders can use the tool to discover opportunities, monitor existing holdings, and identify changing trends more efficiently.
The $22 target is a calculated average of seven analyst price targets, not a guarantee, and it sits within a strikingly wide $14-to-$31 range. A move of roughly 12.9% is modest in percentage terms, but it still depends on Replimune converting an FDA approval and early prescribing interest into durable commercial sales. The strongest supports are the approved product and positive analyst revisions; the largest obstacles are an unproven launch, ongoing losses, dilution, and elevated short interest. Whether the shares reach $22 will likely be decided by the next several quarters of revenue data rather than by near-term momentum.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.
| Ticker / NAME | Correlation To REPL | 1D Price Change % | ||
|---|---|---|---|---|
| REPL | 100% | -2.93% | ||
| IMNN - REPL | 57% Loosely correlated | -2.59% | ||
| SNDX - REPL | 49% Loosely correlated | +6.66% | ||
| KYMR - REPL | 45% Loosely correlated | -1.44% | ||
| NRIX - REPL | 43% Loosely correlated | -3.55% | ||
| ZYME - REPL | 42% Loosely correlated | +3.15% | ||
More | ||||